Clinical trial NCT03360630: Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
Official title: Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined Anti-PD1 in Advanced NSCLC: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Lung Cancer
Neoplasms
Lead sponsor: Capital Medical University
Sponsor class: OTHER
Collaborators: name: Duke University
name: Geneplus-Beijing Co. Ltd.
First posted: 2017-12-04
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed advanced or metastatic NSCLC.
* Patients must have received previously standard therapy for that malignancy or declined to chemotherapy/radiotherapy.
* Estimated life expectancy \> 3 months.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
* Age 18 to 80.
* Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR \<1.5 (unless patient is receiving warfarin in which case PT-INR must be \<3), PTT \<1.5X ULN
* Adequate renal and hepatic function, with serum creatinine \< 1.5 mg/ dL, bilirubin \< 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal.

Exclusion Criteria:

* Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted.
* Patients with serious intercurrent chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.
* Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.
* Concurrent (or within the last 5 years) second malignancy other than non melanoma skin cancer, cervical carcinoma in situ, controlled superficial bladder cancer, or other carcinoma in situ that has been treated.
* Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.
* Patients on chronic steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies or for acute treatment (\<5 days) of intercurrent medical condition such as a gout flare) prior to enrollment.
* Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study.
* Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.

Primary outcomes:
measure: Progression-free survival of the participants
timeFrame: 12 months
Secondary outcomes:
measure: Overall survival of the participants(OS)
timeFrame: 24 months
measure: Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE)
timeFrame: 24 months
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: 24 months
measure: Molecular Tumor Burden Index
timeFrame: 24 months
Other outcomes:
measure: Cell-free tumor DNA
timeFrame: 24 months
measure: Tumor related antigen peptides
timeFrame: 24 months
measure: T cell metaboic activity
timeFrame: 24 months
measure: Microbial bacteria
timeFrame: 24 months
Locations:
city: Beijing
country: China
facility: Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital
Study officials:
References: